MX2014008008A - Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c. - Google Patents
Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.Info
- Publication number
- MX2014008008A MX2014008008A MX2014008008A MX2014008008A MX2014008008A MX 2014008008 A MX2014008008 A MX 2014008008A MX 2014008008 A MX2014008008 A MX 2014008008A MX 2014008008 A MX2014008008 A MX 2014008008A MX 2014008008 A MX2014008008 A MX 2014008008A
- Authority
- MX
- Mexico
- Prior art keywords
- hcv inhibitor
- solid compositions
- pharmaceutically acceptable
- inhibitor
- selected hcv
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000008247 solid mixture Substances 0.000 title abstract 2
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención presenta composiciones sólidas que comprenden un inhibidor de VHC seleccionado en una forma amorfa. En una modalidad, el inhibidor de VHC seleccionado está formulado en una dispersión sólida amorfa que comprende un polímero hidrófilo farmacéuticamente aceptable y preferiblemente un agente tensoactivo farmacéuticamente aceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161581146P | 2011-12-29 | 2011-12-29 | |
US201261645696P | 2012-05-11 | 2012-05-11 | |
PCT/US2012/070349 WO2013101550A1 (en) | 2011-12-29 | 2012-12-18 | Solid compositions comprising an hcv inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014008008A true MX2014008008A (es) | 2014-08-21 |
Family
ID=47470243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008008A MX2014008008A (es) | 2011-12-29 | 2012-12-18 | Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130172239A1 (es) |
EP (2) | EP2907505A3 (es) |
JP (2) | JP5781706B2 (es) |
CN (1) | CN104010631B (es) |
CA (1) | CA2857339C (es) |
DE (1) | DE212012000197U1 (es) |
HK (1) | HK1201186A1 (es) |
MX (1) | MX2014008008A (es) |
WO (1) | WO2013101550A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
ME02196B (me) | 2011-11-16 | 2016-02-20 | Gilead Pharmasset Llc | Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2846778B1 (en) * | 2012-05-07 | 2018-04-25 | Bristol-Myers Squibb Holdings Ireland | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
US8969588B2 (en) * | 2012-06-05 | 2015-03-03 | Gilead Pharmasset Llc | Solid forms of an antiviral compound |
TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
LT2950786T (lt) | 2013-01-31 | 2020-03-10 | Gilead Pharmasset Llc | Dviejų antivirusinių junginių preparatų kompozicija |
EA201591787A1 (ru) * | 2013-03-15 | 2015-12-30 | Ачиллион Фармасьютикалз, Инк. | Таблетки совапревира |
US9732076B2 (en) * | 2013-03-15 | 2017-08-15 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of HCV inhibitor in the amorphous state |
CN105705511A (zh) | 2013-04-12 | 2016-06-22 | 艾其林医药公司 | 用于治疗hcv的氘化核苷前药 |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
EP3021845A1 (en) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN105939715A (zh) * | 2014-02-05 | 2016-09-14 | 默沙东公司 | 抗病毒化合物的固定剂量组合 |
WO2015120014A1 (en) * | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
US20160339074A1 (en) * | 2014-02-05 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pharmaceutical composition of selective hcv ns3/4a inhibitors |
WO2015150561A2 (en) * | 2014-04-03 | 2015-10-08 | Sandoz Ag | Solid composition comprising amorphous sofosbuvir |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
WO2016038542A2 (en) * | 2014-09-10 | 2016-03-17 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
WO2016075588A1 (en) * | 2014-11-11 | 2016-05-19 | Sun Pharmaceutical Industries Limited | Stable amorphous daclatasvir dihydrochloride |
CA2975813A1 (en) * | 2015-02-13 | 2016-08-18 | Sandoz Ag | Pharmaceutical compositions comprising ledipasvir and sofosbuvir |
WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
WO2017021904A1 (en) * | 2015-08-03 | 2017-02-09 | Laurus Labs Private Limited | Daclatasvir free base and process for the preparation thereof |
US20180228827A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US20180221282A1 (en) * | 2015-08-04 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
WO2017023714A1 (en) * | 2015-08-04 | 2017-02-09 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US20180228828A1 (en) * | 2015-08-04 | 2018-08-16 | Merck Sharp & Dohme Corp. | Fixed-dose combinations of antiviral compounds |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN108136033A (zh) | 2015-10-07 | 2018-06-08 | 桑多斯股份公司 | 包含无定形索非布韦的固体药物组合物 |
WO2017072714A1 (en) | 2015-10-30 | 2017-05-04 | Lupin Limited | Stable ledipasvir premix and process of preparation thereof |
BR102017011025A2 (pt) * | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
MX2019001771A (es) | 2016-08-12 | 2019-11-18 | Sandoz Ag | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. |
WO2018078536A1 (en) | 2016-10-26 | 2018-05-03 | Lupin Limited | Stable solid dispersion of sofosbuvir and process for preparation thereof |
CN106727516A (zh) * | 2017-01-10 | 2017-05-31 | 山东省立医院 | 一种治疗丙型肝炎的药物组合物 |
WO2019134971A1 (en) * | 2018-01-04 | 2019-07-11 | Sandoz Ag | Encapsulated particles comprising a pharmaceutically active ingredient |
US11378965B2 (en) | 2018-11-15 | 2022-07-05 | Toyota Research Institute, Inc. | Systems and methods for controlling a vehicle based on determined complexity of contextual environment |
CN113209087B (zh) * | 2020-02-05 | 2023-11-07 | 歌礼药业(浙江)有限公司 | 一种抑制冠状病毒的药物组合物及其用途 |
NL2028762B1 (en) * | 2021-07-16 | 2023-01-23 | Seranovo Holding B V | Micelle-generating formulations for enhanced bioavailability |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100664822B1 (ko) * | 2002-02-01 | 2007-01-04 | 화이자 프로덕츠 인코포레이티드 | 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법 |
TWI389688B (zh) * | 2004-06-08 | 2013-03-21 | Vertex Pharma | Vx-950之形態與調配物及其製備方法與用途 |
CN101494979A (zh) * | 2006-03-20 | 2009-07-29 | 沃泰克斯药物股份有限公司 | 药物组合物 |
US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
PE20091041A1 (es) * | 2007-10-19 | 2009-08-22 | Abbott Gmbh & Co Kg | Producto de dispersion solida que contiene un compuesto a base de n-aril urea |
AU2009279520A1 (en) * | 2008-08-07 | 2010-02-11 | Merck Sharp & Dohme Corp. | Pharmaceutical formulations of an HCV protease inhibitor in a solid molecular dispersion |
BRPI1008918A2 (pt) * | 2009-02-27 | 2016-03-15 | Ortho Mcneil Janssen Pharm | sal amorfo de um inibidor macrocíclico de hcv |
TWI629981B (zh) * | 2009-05-13 | 2018-07-21 | 基利法瑪席特有限責任公司 | 抗病毒化合物 |
SG10201702522UA (en) * | 2009-06-11 | 2017-05-30 | Abbvie Bahamas Ltd | Anti-viral compounds to treat hcv infection |
US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
US8415374B2 (en) * | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
NZ605440A (en) * | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
-
2012
- 2012-12-18 EP EP15156387.1A patent/EP2907505A3/en not_active Withdrawn
- 2012-12-18 US US13/717,993 patent/US20130172239A1/en not_active Abandoned
- 2012-12-18 DE DE212012000197.2U patent/DE212012000197U1/de not_active Expired - Lifetime
- 2012-12-18 JP JP2014550335A patent/JP5781706B2/ja active Active
- 2012-12-18 CN CN201280064815.5A patent/CN104010631B/zh active Active
- 2012-12-18 EP EP12809070.1A patent/EP2797586A1/en not_active Withdrawn
- 2012-12-18 WO PCT/US2012/070349 patent/WO2013101550A1/en active Application Filing
- 2012-12-18 MX MX2014008008A patent/MX2014008008A/es unknown
- 2012-12-18 CA CA2857339A patent/CA2857339C/en active Active
-
2015
- 2015-02-16 HK HK15101710.0A patent/HK1201186A1/xx unknown
- 2015-07-14 JP JP2015140513A patent/JP2015227352A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104010631A (zh) | 2014-08-27 |
JP2015227352A (ja) | 2015-12-17 |
CA2857339A1 (en) | 2013-07-04 |
CN104010631B (zh) | 2016-08-17 |
CA2857339C (en) | 2015-11-17 |
EP2797586A1 (en) | 2014-11-05 |
JP2015503560A (ja) | 2015-02-02 |
US20130172239A1 (en) | 2013-07-04 |
EP2907505A3 (en) | 2015-12-30 |
DE212012000197U1 (de) | 2014-09-05 |
JP5781706B2 (ja) | 2015-09-24 |
WO2013101550A1 (en) | 2013-07-04 |
HK1201186A1 (en) | 2015-08-28 |
EP2907505A2 (en) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014008008A (es) | Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c. | |
MY164607A (en) | Solid compositions | |
MY156888A (en) | Solid Compositions | |
ME03347B (me) | PARAZITICIDNE KOMPOZICIJE KOJE SADRŽE IZOKSAZOLINSKO AKTIVNO SREDSTVO, POSTUPCI l UPOTREBE POVEZANE SA NJIMA | |
IL249141A0 (en) | Preparations for the treatment of parasites containing a large number of active factors, their methods and uses | |
IL227682A0 (en) | Compounds suppressing 17-il and γ- ifn, preparations containing them and their uses | |
PH12014502858A1 (en) | Racecadotril lipid compositions | |
WO2012139074A3 (en) | Migrastatins and uses thereof | |
CR20120632A (es) | Composiciones sòlidas |